Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ADAM23
REST API REST API
Homo sapiens
ADAM23 is differentially expressed in 267 experiments: 177 organism parts: lung, brain, ... (175 more);, 210 disease states: normal, control, ... (208 more);, 97 cell types 403 cell lines 27 compound treatments and 74 other conditions.
Synonyms MDC3
Orthologs ADAM23 (Gallus gallus)   Adam23 (Mus musculus)   ADAM23 (1 of 2) (Danio rerio)   adam23a (Danio rerio)   A4FUX7_BOVIN (Bos taurus)   Adam23 (Rattus norvegicus)   adam23 (Xenopus laevis)   ADAM23 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, protein binding, metalloendopeptidase activity, metallopeptidase activity, extracellular region, cell adhesion, integral to plasma membrane, integrin binding, proteolysis, central nervous system development, zinc ion binding
InterPro Term EGF_extracell, Peptidase_M12B_N, Blood-coag_inhib_Disintegrin, ADAM_Cys-rich, EGF_3, Peptidase_M12B
UniProt Accession Q53RX4, Q53TC0, Q53TK5, O75077, E7EWD3, F8WDS0
Search EB-eye ENSG00000114948
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-7224, E-GEOD-3526, ... (26 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, ... (38 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-5823, E-GEOD-20081, E-GEOD-19639
HL-60
1
3
E-MTAB-37, E-GEOD-24147, E-GEOD-5258, E-GEOD-96
A673
2
E-MTAB-62, E-MTAB-37
A549
2
E-GEOD-6013, E-GEOD-3202
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
GM15510
2
E-GEOD-22639, E-GEOD-19466
397 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, ... (49 experiments)

Factor Value U/D Experiments
human embryonic stem cell
3
E-GEOD-20033, E-GEOD-18147, E-GEOD-18265
1
2
E-TABM-145, E-TABM-130
fibroblast
2
E-GEOD-3204, E-GEOD-3920
induced pluripotent stem cell
2
E-GEOD-18147, E-GEOD-18265
mononuclear
2
E-GEOD-13987, E-GEOD-26672
stromal cell
1
2
E-GEOD-10797, E-GEOD-1460, E-GEOD-3998
91 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-MEXP-1121, E-MEXP-2280, E-GEOD-16363, ... (49 experiments)

Factor Value U/D Experiments
control
1
4
E-GEOD-21912, E-GEOD-8121, E-GEOD-16363, E-GEOD-20295, E-GEOD-20602 ... (5 experiments)
astrocytoma
2
E-MTAB-62, E-GEOD-4290
head and neck squamous cell carcinoma
2
E-MTAB-62, E-GEOD-2379
Burkitt's lymphoma
2
E-GEOD-1880, E-GEOD-96
acute promyelocytic leukemia
2
E-GEOD-96, E-MTAB-62
colon carcinoma
2
E-MTAB-62, E-MTAB-37
204 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5741, E-GEOD-15205, E-GEOD-5824, E-TABM-868, ... (18 experiments)

Factor Value U/D Experiments
none
1
5
E-GEOD-412, E-TABM-868, E-GEOD-7400, E-MEXP-1230, E-GEOD-7307, ... (6 experiments)
unknown
1
E-GEOD-7307
interleukin-26 (Homo sapiens)
1
E-GEOD-7216
TNF
1
1
E-GEOD-15205
non-steroidal anti-inflammatory drugs
1
E-GEOD-1919
glucose
1
E-MEXP-941
21 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
68
2
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (9 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-MEXP-2359, E-MEXP-2283, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-MEXP-2280, E-GEOD-21138, E-GEOD-3013

Environmental stress
studied in E-GEOD-1643

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, E-MTAB-108, ... (8 experiments)

Genotype
studied in E-GEOD-17476, E-GEOD-2466, E-TABM-868, E-TABM-601, E-MEXP-958, ... (16 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-13073, E-MEXP-1220, E-GEOD-12773, E-GEOD-20504, E-MEXP-1446, ... (9 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-GEOD-16363, ... (26 experiments)

Infection
studied in E-GEOD-12108, E-MEXP-561

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-1309, E-GEOD-22309, E-GEOD-21750, E-GEOD-1460, E-GEOD-7114, ... (6 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246

Qpcr egfr dct
studied in E-GEOD-5851

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

Sex
studied in E-GEOD-2466, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926

Tissue
studied in E-GEOD-30573

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19815

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4922, E-TABM-147

Tumor size
studied in E-GEOD-6532

Processing time: 0.426 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM